Abstract
The prevalence of depressive disorders in modern society is quite high, which is an important medical and social issue throughout the world. The role of psychosocial factors in the development of cardiovascular diseases, as well as the high comorbidity of cardiac pathology and depression in recent decades, are beyond doubt. Therapy for depressive disorders in cardiac patients should combine efficacy and safety, as well as ensure patient adherence to therapy. Despite the rather large number and wide availability of antidepressants, including those that are relatively safe in relation to the treatment of depression in cardiovascular pathology, there is a need to search for new depressive disorders treatment options that are even safer and more effective, especially in patients with various comorbid pathologies and concomitant therapy.
Publisher
PANORAMA Publishing House
Reference25 articles.
1. 1. World Health Organization. Depression. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/depression (accessed 12 May 2022). (In Russ.)
2. 2. Iliina E. S., Filippova N.V., Barylnik Iu.B. Farmakogenetika antidepressantov (ot istorii k sovremennosti) [Pharmacogenetics of antidepressants (from history to the present)]. Vestnik nevrologii, psikhiatrii i neirokhirurgii [Bulletin of Neurology, Psychiatry and Neurosurgery] 2021; 9: 713-729. (In Russ.)
3. 3. Glushchenko V.A., Iraklienko E.K. Depressiia u kardiologicheskikh patsientov [Depression in cardiac patients]. Alma mater Vestnik vysshei shkoly [Higher Education Bulletin] 2017; 1 (2): 23. (In Russ.)
4. 4. Piña I. L., Di Palo K. E., Ventura H.O. Psychopharmacology and Cardiovascular Disease. J Am Coll Cardiol. 2018; 71 (20): 2346- 2359. doi: 10.1016/j.jacc.2018.03.458.
5. 5. Ariyo A.A., Haan М., Tangen С.М., еt al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation 2000; 102: 1773-1779. doi: 10.1161/01.cir.102.15.1773.